Madrigal Pharmaceuticals Inc (MDGL)
217.01
+5.28
(+2.49%)
USD |
NASDAQ |
May 16, 16:00
217.01
0.00 (0.00%)
After-Hours: 16:02
Madrigal Pharmaceuticals Free Cash Flow: -391.12M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -391.12M |
| December 31, 2023 | -325.71M |
| September 30, 2023 | -303.28M |
| June 30, 2023 | -277.13M |
| March 31, 2023 | -259.21M |
| December 31, 2022 | -225.07M |
| September 30, 2022 | -214.69M |
| June 30, 2022 | -201.20M |
| March 31, 2022 | -190.62M |
| December 31, 2021 | -184.13M |
| September 30, 2021 | -190.92M |
| June 30, 2021 | -193.17M |
| March 31, 2021 | -170.55M |
| December 31, 2020 | -157.90M |
| September 30, 2020 | -115.35M |
| June 30, 2020 | -78.82M |
| March 31, 2020 | -66.10M |
| December 31, 2019 | -41.80M |
| September 30, 2019 | -35.65M |
| June 30, 2019 | -29.58M |
| March 31, 2019 | -23.40M |
| December 31, 2018 | -25.53M |
| September 30, 2018 | -25.20M |
| June 30, 2018 | -24.90M |
| March 31, 2018 | -27.31M |
| Date | Value |
|---|---|
| December 31, 2017 | -22.44M |
| September 30, 2017 | -21.78M |
| June 30, 2017 | -26.07M |
| March 31, 2017 | -20.95M |
| December 31, 2016 | -17.61M |
| September 30, 2016 | -13.43M |
| June 30, 2016 | 30.31M |
| March 31, 2016 | 15.20M |
| December 31, 2015 | -3.142M |
| September 30, 2015 | -21.32M |
| June 30, 2015 | -74.41M |
| March 31, 2015 | -77.55M |
| December 31, 2014 | -79.07M |
| September 30, 2014 | -78.57M |
| June 30, 2014 | -76.57M |
| March 31, 2014 | -75.98M |
| December 31, 2013 | -78.18M |
| September 30, 2013 | -72.02M |
| June 30, 2013 | -68.88M |
| March 31, 2013 | -61.73M |
| December 31, 2012 | -54.64M |
| September 30, 2012 | -52.90M |
| June 30, 2012 | -51.51M |
| March 31, 2012 | -50.54M |
| December 31, 2011 | -47.99M |
Free Cash Flow Range, Past 5 Years
-391.12M
Minimum
Mar 2024
-29.58M
Maximum
Jun 2019
-182.60M
Average
-190.77M
Median
Free Cash Flow Benchmarks
| Viking Therapeutics Inc | -54.87M |
| Eli Lilly and Co | -3.896B |
| Akero Therapeutics Inc | -155.88M |
| 89bio Inc | -138.82M |
| Geron Corp | -184.70M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -149.16M |
| Cash from Investing (Quarterly) | 98.05M |
| Cash from Financing (Quarterly) | 573.71M |
| Free Cash Flow Per Share (Quarterly) | -7.475 |
| Free Cash Flow Yield | -9.42% |